Loading patent…
AssigneesIcahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme Corp.
InventorsPeter PALESE, Adolfo GARCIA-SASTRE, Dmitriy ZAMARIN, Svetlana SADEKOVA, Rachel Allison ALTURA, Uyen PHAN, Brian B. HAINES, Jedd D. WOLCHOK
Estimating the term…
Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 (“PD-1”) or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.
-42. (canceled)
A method for treating cancer in a human subject, comprising administering to the human subject a pharmaceutical composition of a chimeric NDV in an admixture with a pharmaceutical acceptable carrier, wherein the chimeric NDV comprises a packaged genome, said packaged genome comprising a transgene encoding a human IL-12, wherein the IL-12 comprises the amino acid sequence set forth in SEQ ID NO:39 or 22.
A method for treating cancer in a human subject, comprising administering to the human subject a pharmaceutical composition of a chimeric NDV in an admixture with a pharmaceutical acceptable carrier, wherein the chimeric NDV comprises a packaged genome, said packaged genome comprising a transgene encoding a human IL-12, wherein the IL-12 comprises the amino acid sequence set forth in SEQ ID NO:43 or 42.
Dependencies are inferred from the claim text.